Skyepharma ended 2015 with a flurry of positive news. The partnering deal with Mundipharma for SKP-2076, Pacira’s announcement of a resolution achieved with the FDA on Exparel coupled with an encouraging FY15 pre-close update marks a good start for 2016. Skyepharma has entered into a feasibility and option agreement for SKP-2076 with Mundipharma, the partner of choice in our view, and the timely announcement could ensure seamless development once SKP-2076 feasibility studies complete by
18 Jan 2016
A shining start to 2016
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A shining start to 2016
Skyepharma ended 2015 with a flurry of positive news. The partnering deal with Mundipharma for SKP-2076, Pacira’s announcement of a resolution achieved with the FDA on Exparel coupled with an encouraging FY15 pre-close update marks a good start for 2016. Skyepharma has entered into a feasibility and option agreement for SKP-2076 with Mundipharma, the partner of choice in our view, and the timely announcement could ensure seamless development once SKP-2076 feasibility studies complete by